Related Experiment Videos
Homovanilic acid in Huntington's disease and Sydenham's chorea
Insights
This study found lower levels of homovanilic acid (HVA), a dopamine metabolite, in patients with Huntington's disease and Sydenham's chorea, suggesting reduced dopamine release in the brain for both conditions.
Area of Science:
- Neuroscience
- Biochemistry
- Neurology
Background:
- Huntington's disease (HD) and Sydenham's chorea (SC) are characterized by involuntary movements.
- Dopamine pathways are implicated in motor control and neurodegenerative disorders.
- Homovanilic acid (HVA) is a major metabolite of dopamine, reflecting its turnover in the brain.
Purpose of the Study:
- To investigate cerebral dopamine release in patients with Huntington's disease and Sydenham's chorea.
- To assess the levels of homovanilic acid (HVA) in cerebrospinal fluid (CSF) as an indicator of dopamine metabolism.
- To evaluate the effect of probenecid, a dopamine transport inhibitor, on HVA levels in these patient groups.
Main Methods:
- Determined homovanilic acid (HVA) concentrations in the lumbar cerebrospinal fluid (CSF) of patients.
- Included 12 patients with Huntington's disease and 12 with Sydenham's chorea.
- Measured HVA levels before and after probenecid administration to assess dopamine turnover.
Main Results:
- Mean HVA concentrations were lower in Huntington's disease patients compared to controls, particularly in those with motor impairments.
- Sydenham's chorea patients showed normal basal HVA but significantly reduced accumulation after probenecid.
- No correlation was found between CSF HVA levels and disease severity, duration, or age in Huntington's disease.
Conclusions:
- Results suggest a decrease in cerebral dopamine release in both Huntington's disease and Sydenham's chorea.
- HVA levels in CSF can serve as a biomarker for dopamine dysregulation in choreiform movement disorders.
- Further research into dopamine system dysfunction is warranted for these conditions.
Abstract:
Homovanilic acid (HVA) was determined in the lumbar CSF of 12 patients with Huntington's disease and 12 with Sydenham's chorea before and after probenecid administration. The means of HVA concentration (basal and after probenecid) were lower in those with Huntington's disease than in controls, and were even lower in a sub-group characterised by increased tone and slowness of voluntary movement. There was no correlation between CSF HVA values and the severity of abnormal movements, nor with length of the illness and age of the patients with Huntington's disease. The mean basal HVA concentration did not differ from controls in those with Sydenham's chorea but the accumulation with probenecid was significantly lower. These results suggest a decrease in cerebral dopamine release in both forms of chorea.